Facebook Tracking Image

National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN and AstraZeneca Quality of Care & Clinical Care Pathways in Unresectable Stage III/Stage IV NSCLC Funding Opportunity: Submit LOIs by July 9, 2019
NCCN AstraZeneca Quality of Care Evaluations in Advanced Ovarian Cancer Funding Opportunity: Submit LOIs by July 22, 2019
NCCN and Pfizer Enhancing Academic-Community-Patient Partnerships in Metastatic Breast Cancer Care Funding Opportunity:  Submit Proposals by August 28, 2019
ORP Recent News
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources
ORP Disclosure Policy
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources



Fox Chase Cancer Center
Philadelphia, Pennsylvania
1.888.FOX CHASE (1.888.369.2427)
www.foxchase.org

Make an Appointment

For Health Professionals

 

Find a clinical trial >

Profile

Fox Chase Cancer Center is one of 50 National Cancer Institute (NCI) Comprehensive Cancer Centers, conducting a broad array of nationally competitive basic, translational, and clinical research, and offering a number of multidisciplinary treatment options to patients with all types of cancers, including rare and difficult-to-manage tumors, and special programs in cancer prevention, detection, survivorship, and community outreach.

Fox Chase scientists and physicians have long collaborated together in conducting clinical research, basic laboratory research and population research. Combining research in many disciplines with patient care enables Fox Chase to translate new research findings into medical applications that may become models for improved cancer care.

Fox Chase's broad-based program of clinical research includes trials of new prevention, diagnostic and treatment techniques. About 200-300 clinical trials are under way at any one time. Fox Chase is also involved in developing trials to test new agents that may prevent cancer in high-risk individuals and is an active participant in national cancer prevention studies.

Fox Chase has approximately 2,400 employees. Research is conducted in more than 90 laboratories by a staff of 358 physicians and scientists who hold MDs, PhDs, or both. Investigators at Fox Chase have received many awards and honors, including Nobel Prizes in medicine and chemistry, a Kyoto Prize in Basic Sciences, a Lasker Clinical Research Award, American Cancer Society Medals of Honor, memberships in the National Academy of Sciences, and induction into the National Inventors Hall of Fame.

As an institution, the Center also has achieved many distinctions, including accreditation by the American College of Surgeons' Commission on Cancer with commendation and Magnet status for nursing excellence from the American Nurses Credentialing Center. Fox Chase became the nation's first comprehensive cancer center and Pennsylvania's first hospital to earn Magnet status in September 2000 and has since earned five re-designations to become the first institution in Pennsylvania to achieve this distinction. In addition, the department of radiation oncology is accredited by the American College of Radiology, a distinction showing that Fox Chase meets the highest national quality standards for radiation treatment. Finally, Fox Chase's Women's Cancer Center is accredited by the American College of Radiology as a Breast Imaging Center of Excellence, as well as by the National Accreditation Program for Breast Centers (NAPBC).

Fox Chase is a founding member of the National Comprehensive Cancer Network. The Center's participation in NCCN includes representation on its Board of Directors. In addition, many Fox Chase physicians are members or leaders of the NCCN's Guidelines panels. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)—the recognized standard of care in cancer treatment—offer the most comprehensive and up-to-date treatment guidelines in medicine. Fox Chase also takes part in cancer outcome studies for many types of cancers, including lymphoma, breast, colorectal, lung, and ovarian cancers.

 

No. of Inpatient
Beds
(Medical/Surgical)
No. of
Admissions
Average
Length of Stay (days)
No. of
Outpatient Visits
No. of Oncologists
(Medical, Radiation, and Surgical)
100 4,304 4.73 113,546 90 (including oncology fellows)